SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) — Exagen Inc. XGN, a leading provider of autoimmune testing solutions, today announced the appointment of Andrew L. Concoff, MD FACR, CAQSM, as Chief Innovation Officer. In this role, Dr. Concoff will lead the company’s rheumatoid arthritis medical initiatives, including AVISE® RADR platform (Rheumatoid Arthritis Drug Response). dr Concoff will play a key role in strategy, business development, portfolio management, pipeline prioritization and new business creation, and driving innovative access partnerships with payers and governments worldwide.
“Exagen is deeply committed to rheumatology, where we believe there is a significant unmet need in the diagnosis, prognosis and monitoring of autoimmune diseases that our tests can uniquely address,” said Ron Rocca, President and Chief Executive Officer of exagen. “We are delighted, Dr. Welcoming Concoff to our Executive Leadership Team as we move into Exagen’s next phase of innovation. We believe his clinical experience in rheumatology and his leadership will be instrumental in our quest to transform the continuum of care for autoimmune diseases.”
dr Concoff has over fifteen years of clinical practice in rheumatology, having completed his fellowship at the University of California, Los Angeles. He earned a BS in Psychobiology from UCLA and an MD from the University of Texas Medical School at Houston, where he also completed courses for a Masters in Clinical Research. dr Concoff comes to Exagen from United Rheumatology, where his work as Executive Vice President, Chief Medical Officer enables him to create, model and implement value-based programs with payers, quality improvement initiatives with pharmaceutical manufacturers and other clinical care innovations with stakeholders across the musculoskeletal ecosystem. He is also a Fellow of the American College of Rheumatology and has worked on numerous…
